{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:33:20Z","timestamp":1785792800505,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jpba.2025.117128","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:15:07Z","timestamp":1755875707000},"page":"117128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS\/MS"],"prefix":"10.1016","volume":"267","author":[{"given":"Anupam","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushikesh","family":"Biradar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-5322","authenticated-orcid":false,"given":"Sukhendu","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.117128_bib1","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jpba.2025.117128_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2025.117128_bib3","unstructured":"Diabetes. \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes\/\u3009, 2024 (accessed 25 March 2025)."},{"key":"10.1016\/j.jpba.2025.117128_bib4","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.jpba.2025.117128_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jpba.2025.117128_bib6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11095-006-9217-9","article-title":"The evolving role of drug metabolism in drug discovery and development","volume":"24","author":"Yengi","year":"2007","journal-title":"Pharm. Res"},{"key":"10.1016\/j.jpba.2025.117128_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/bdd.660","article-title":"Metabolites in safety testing: metabolite identification strategies in discovery and development","volume":"30","author":"Nedderman","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jpba.2025.117128_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.117005","article-title":"Metabolic profiling of chrysotoxine: structural elucidation of phase I metabolites and reactive intermediate identification by liquid chromatography tandem mass spectrometry","volume":"265","author":"Jiao","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jpba.2015.04.023","article-title":"Pharmacokinetic profile and metabolite identification of yuanhuapine, a bioactive component in daphne genkwa by ultra-high performance liquid chromatography coupled with tandem mass spectrometry","volume":"112","author":"Chen","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116965","article-title":"Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112","volume":"177","author":"Sun","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.jpba.2025.117128_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115718","article-title":"The in vitro metabolism of GMDTC in liver microsomes of human, monkey, dog, rat and mouse: metabolic stability assessment, metabolite identification and interspecies comparison","volume":"236","author":"Hu","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jpba.2015.09.029","article-title":"Identification of in vitro metabolites of ethylphenidate by liquid chromatography coupled to quadrupole time-of-flight mass spectrometry","volume":"117","author":"Negreira","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jpba.2018.06.050","article-title":"Identification and structural characterization of in vivo metabolites of balofloxacin in rat plasma, urine and feces samples using Q-TOF\/LC\/ESI\/MS\/MS: in silico toxicity studies","volume":"159","author":"Shankar","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpba.2016.03.027","article-title":"Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254","volume":"125","author":"Dib","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115797","article-title":"Development and validation of LC-MS\/MS method for estimating the pharmacokinetics, protein binding, and metabolic stability of soluble epoxide hydrolase inhibitor EC5026","volume":"237","author":"Biradar","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115258","article-title":"Development and validation of LC-MS\/MS method for determining the metabolic stability, pharmacokinetics, and dose proportionality of a novel anti-inflammatory cofilin inhibitor","volume":"226","author":"Alsegiani","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib17","unstructured":"FDA, Bioanalytical Method Validation Guidance for Industry, 2018. Recommendations. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (accessed 25 March 2025)."},{"key":"10.1016\/j.jpba.2025.117128_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0041-008X(03)00128-5","article-title":"An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons","volume":"189","author":"Brandon","year":"2003","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.jpba.2025.117128_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.123011","article-title":"A systematic UHPLC-Q-TOF-MS\/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway","volume":"1185","author":"Sharma","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2025.117128_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116116","article-title":"Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry","volume":"244","author":"Dey","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpba.2018.05.008","article-title":"in vitro and in vivo metabolic investigation of the palbociclib by UHPLC-Q-TOF\/MS\/MS and in silico toxicity studies of its metabolites","volume":"157","author":"Chavan","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jpba.2014.01.003","article-title":"Metabolites identification of harmane in vitro\/in vivo in rats by ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry","volume":"92","author":"Li","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117128_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2012.11.049","article-title":"Combined data mining strategy for the systematic identification of sport drug metabolites in urine by liquid chromatography time-of-flight mass spectrometry","volume":"761","author":"Dom\u00ednguez-Romero","year":"2013","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2025.117128_bib24","unstructured":"M.K. Matlock, T.B. Hughes, S.J. Swamidass, XenoSite-Server: A Web-Available Site of Metabolism Prediction Tool. http:\/\/bioinformatics.oxfordjournals.org\/."},{"key":"10.1016\/j.jpba.2025.117128_bib25","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1021\/ci400518g","article-title":"XenoSite: accurately predicting cyp-mediated sites of metabolism with neural networks","volume":"53","author":"Zaretzki","year":"2013","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.jpba.2025.117128_bib26","doi-asserted-by":"crossref","first-page":"25419","DOI":"10.1074\/jbc.R110.200055","article-title":"Drug metabolite profiling and identification by High-resolution mass Spectrometry*","volume":"286","author":"Zhu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2025.117128_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117761","article-title":"A novel approach to exploit small-molecule glucagon-like peptide-1 receptor agonists with high potency","volume":"107","author":"Wang","year":"2024","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.jpba.2025.117128_bib28","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jpba.2025.117128_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11030-022-10590-7","article-title":"Recent advances in the area of plant-based anti-cancer drug discovery using computational approaches","volume":"28","author":"Das","year":"2024","journal-title":"Mol. Divers"},{"key":"10.1016\/j.jpba.2025.117128_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127516","article-title":"Phytometabolomics of wedelia chinensis leaves extracted with natural deep eutectic solvents: bioactivities and anti-diabetic mechanisms","volume":"428","author":"Sharma","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.jpba.2025.117128_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jpba.2025.117128_bib32","doi-asserted-by":"crossref","first-page":"16779","DOI":"10.1039\/D2RA00373B","article-title":"Computational identification of natural product inhibitors against EGFR double mutant (T790M\/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach","volume":"12","author":"Agarwal","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2025.117128_bib33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.tiv.2006.06.003","article-title":"Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements","volume":"20","author":"Sohlenius-Sternbeck","year":"2006","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.jpba.2025.117128_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/03602539109029764","article-title":"Species differences in metabolism and pharmacokinetics: are we close to an understanding?","volume":"23","author":"Smith","year":"1991","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.jpba.2025.117128_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.jpba.2025.117128_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2025.117128_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/dmd.115.067900","article-title":"Interindividual variability in cytochrome p450\u2013mediated drug metabolism","volume":"44","author":"Tracy","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2025.117128_bib38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cbdv.200690111","article-title":"The biochemistry of drug metabolism \u2013 an introduction","volume":"3","author":"Testa","year":"2006","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.jpba.2025.117128_bib39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2025.117128_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.102.033340","article-title":"Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model","volume":"302","author":"Marier","year":"2002","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.jpba.2025.117128_bib41","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.apsb.2022.03.009","article-title":"Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development","volume":"12","author":"Lai","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jpba.2025.117128_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108020","article-title":"Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: focus on the regulation of gene expression and enzyme activity","volume":"233","author":"Pang","year":"2022","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.jpba.2025.117128_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12551-013-0130-2","article-title":"Receptor-ligand molecular docking","volume":"6","author":"Guedes","year":"2014","journal-title":"Biophys. Rev."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:47:35Z","timestamp":1772819255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525004698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0731708525004698"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117128","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117128"}}